新型脲基青霉素Bay k 4999与氨基糖苷类药物联合应用对铜绿假单胞菌、大肠杆菌、肺炎克雷伯菌和变形杆菌菌株的体外抗菌效果。

In vitro efficacy of Bay k 4999, a new ureido-penicillin, in combination with aminoglycosides against Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Proteus strains.

作者信息

Daschner F D, Steffens A, Langmaack H

出版信息

Chemotherapy. 1979;25(5):282-5. doi: 10.1159/000237852.

Abstract

The in vitro effects of Bay k 4999 in combination with gentamicin, tobramycin, amikacin sisomicin and netilmicin in bacteriostatic (MIC) and bactericidal (MBC) concentrations were compared using the checkerboard dilution technique against 20 different strains of Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and indole-positive-negative Proteus species. On average 63% of Bay k 4999-aminoglycoside (AG) combinations inhibited Pseudomonas, Proteus and Klebsiella strains additively and/or synergistically in bacteriostatic as well as in bactericidal concentrations as compared to only 14% additive or synergistic activity on E. coli. 35% of the combinations tested proved to be synergistic in K. pneumoniae, 20% in Proteus, 13% in Pseudomonas, but only 5% in E. coli. No significant differences between various Bay k 4999-AG combination effects could be demonstrated.

摘要

使用棋盘稀释技术，比较了Bay k 4999与庆大霉素、妥布霉素、阿米卡星、西索米星和奈替米星联合应用时在抑菌（MIC）和杀菌（MBC）浓度下对20种不同菌株的体外作用，这些菌株包括铜绿假单胞菌、大肠杆菌、肺炎克雷伯菌以及吲哚阳性和阴性的变形杆菌属。平均而言，与对大肠杆菌仅有14%的相加或协同活性相比，Bay k 4999 - 氨基糖苷类（AG）组合在抑菌和杀菌浓度下对铜绿假单胞菌、变形杆菌和克雷伯菌菌株的相加和/或协同抑制率平均为63%。在测试的组合中，35%在肺炎克雷伯菌中表现为协同作用，20%在变形杆菌中，13%在铜绿假单胞菌中，但在大肠杆菌中仅为5%。未发现不同Bay k 4999 - AG组合效应之间存在显著差异。